Nanomedicine

[Perspectives] Dodging Drug-Resistant Cancer with Diamonds

When treating metastatic tumors, chemoresistance can cause problems. A report in this issue of Science Translational Medicine demonstrates the potential of nanodiamond carriers (2 to 8 nanometers) for treating cancers with drug-efflux–based chemoresistance. Nanodiamond-mediated delivery of the chemotherapeutic doxorubicin (Dox) allowed for prolonged activity and increased apoptosis with decreased toxicity when compared with free Dox in liver cancer cells in culture as well as in vivo in mouse liver tumors. This finding may represent a broadly applicable strategy for overcoming adenosine 5′-triphosphate (ATP)–binding cassette (ABC) drug transporter–mediated resistance during cancer chemotherapy.

Merkel, T. J., DeSimone, J. M

Share

About Richard Suder, CFA, CFP®

As the founder of Auri Elan Financial Group, I am an experienced independent financial advisor and insurance agent specializing in providing comprehensive and objective investment consultation, financial and insurance planning to individual investors, companies, select group of affluent families and entrepreneurs. Please contact me for a complimentary Portfolio Review. You deserve nothing less than a CFP and a CFA Charterholder for your finance! Securities and Advisory Services offered through LPL Financial. A Registered Investment Advisor, Member FINRA/SIPC.
This entry was posted in Research. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>